3M
MMM
$155.34
+0.41%
3M is a multinational conglomerate operating across safety and industrial, transportation and electronics, and consumer segments, selling tens of thousands of products from sponges to respirators. As a diversified industrial giant with a century-long track record of innovation and a recent spin-off of its healthcare business (Solventum), the company is navigating a transformation toward a leaner, more focused industrial portfolio. The current investor narrative centers on margin recovery, the impact of the Solventum separation, and strategic moves like the $1.95 billion fire safety acquisition, while the stock has shown resilience amid broader market inflation concerns.…
MMM
3M
$155.34
Related headlines
MMM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on 3M's 12-month outlook, with a consensus price target around $201.94 and implied upside of +30.0% versus the current price.
Average Target
$201.94
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$124 - $202
Analyst target range
Seven analysts cover 3M, with a consensus leaning neutral to slightly bullish. Ratings include 1 Underperform (RBC Capital), 2 Equal Weight/Neutral (Morgan Stanley, Citigroup), 1 Hold (Deutsche Bank), 1 Overweight (Wells Fargo), and 1 Buy (UBS). The average target price is not explicitly provided, but based on estimated EPS of $11.415 and a forward P/E of 16.9x, the implied target is ~$193. That would represent +20% upside from the current price of $160.44. The consensus is cautiously optimistic, with a mix of hold and buy ratings. The target range is wide: low EPS estimate of $11.25 implies ~$190, high EPS of $11.67 implies ~$197. The high target assumes successful margin recovery and growth from the fire safety acquisition, while the low target prices in continued margin pressure and slower organic growth. Recent rating actions show stability, with most firms maintaining their ratings since early 2026, though JP Morgan downgraded from Overweight to Neutral in January 2026. The spread between low and high is about 3.7%, indicating relatively high conviction among analysts, but the limited number of analysts (7) suggests moderate institutional interest.
Drowning in data?
Find the real signal!
MMM Technical Analysis
The stock is in a recovery phase after a significant downtrend, with a 1-year price change of +4.2%, underperforming the S&P 500's +19.1% gain. Currently trading at $160.44, it sits at 60% of its 52-week range ($139.34 low to $177.41 high), suggesting it is closer to the low end but has bounced off the lows. This positioning indicates a potential value opportunity if the recovery continues, but also reflects lingering bearish sentiment relative to the broader market. Short-term momentum is positive, with a 1-month change of +4.93% and a 3-month change of +11.05%, accelerating from the 6-month decline of -0.85%. This divergence—short-term strength against a weak longer-term trend—could signal a trend reversal or a temporary pullback within a broader downtrend. The relative strength vs. SPY is +6.18% over 1 month but -14.9% over 1 year, confirming the stock is gaining ground recently but still lagging significantly on a longer horizon. Key support is at the 52-week low of $139.34, while resistance is at the 52-week high of $177.41. A breakout above $177.41 would signal a strong reversal, while a breakdown below $139.34 could lead to further downside. Beta of 1.081 indicates slightly higher volatility than the market, meaning the stock may amplify market moves, which is important for risk management.
Beta
1.08
1.08x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$139-$177
Price range past year
Annual Return
-0.4%
Cumulative gain past year
| Period | MMM Return | S&P 500 |
|---|---|---|
| 1m | -0.7% | +2.0% |
| 3m | +3.3% | +10.6% |
| 6m | -6.0% | +8.3% |
| 1y | -0.4% | +20.4% |
| ytd | -4.0% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MMM Fundamental Analysis
Revenue in the latest quarter (Q4 2025) was $6.133 billion, up 2.05% year-over-year, but down from $6.517 billion in Q3 2025, showing a sequential decline. The multi-quarter trend shows revenue fluctuating around $6.0-6.5 billion, with growth decelerating from earlier quarters (e.g., Q1 2025 revenue was $5.954 billion). Segment-wise, Safety and Industrial contributed $2.865 billion (44%), Transportation and Electronics $1.961 billion (36%), and Consumer $1.214 billion (20%), with the corporate nonsegment adding $93 million. The growth trajectory is modest and uneven, implying the investment case hinges on margin expansion and cost discipline rather than top-line acceleration. Net income in Q4 2025 was $577 million, with a net margin of 9.4%, down from 12.8% in Q3 2025 and 18.7% in Q1 2025, indicating margin compression. Gross margin was 33.6% in Q4 2025, a decline from 41.8% in Q3 2025 and 40.9% in Q1 2025, suggesting cost pressures or mix shifts. Operating margin fell to 12.9% from 24.7% in Q3 2025. The company is profitable but margins are volatile; the trajectory shows a recent deterioration, which is a concern for earnings quality. Free cash flow (TTM) was $1.396 billion, with Q4 2025 FCF of $1.335 billion, a strong recovery from negative FCF in Q2 2025 (-$1.162 billion). The debt-to-equity ratio is 2.75, indicating significant leverage, and ROE is 69.1%, boosted by high leverage. Current ratio of 1.71 suggests adequate liquidity. The company generated $1.583 billion in operating cash flow in Q4 2025, covering capital expenditures of $248 million, but the high debt load (debt/equity 2.75) implies reliance on debt markets, increasing financial risk.
Quarterly Revenue
$6.1B
2025-12
Revenue YoY Growth
+2.05%
YoY Comparison
Gross Margin
33.56%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MMM Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 26.5x, while the forward P/E is 16.9x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests optimism about future profitability, likely driven by cost savings from the healthcare spin-off and operational improvements. Compared to the industry (Conglomerates), 3M's trailing P/E of 26.5x is above the sector average (data not provided, but typically lower for mature industrials). The P/S ratio of 3.43x and EV/EBITDA of 15.9x also indicate a premium valuation. This premium may be justified by 3M's strong brand, R&D capabilities, and recent restructuring efforts, but it also leaves little room for error. Historically, 3M's trailing P/E has ranged from around 12x to 37x over the past few years (based on historical ratios data). The current 26.5x is near the middle of that range, but above the lows seen in 2023-2024 (e.g., 13.7x in Q3 2024). This suggests the stock is not at extreme valuation levels but is pricing in a recovery that has yet to fully materialize in earnings.
PE
26.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~198x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.9x
Enterprise Value Multiple

